J Korean Neurol Assoc.
2022 May;40(2):176-180. 10.17340/jkna.2022.2.14.
Plasmapheresis for a Female with Cryptogenic New-Onset Refractory Status Epilepticus Not Benefiting from Monoclonal Antibody Therapy
- Affiliations
-
- 1Department of Neurology, Gyeongsang National University Hospital, Jinju, Korea
- 2Department of Neurology, Gyeongsang National University College of Medicine, Jinju, Korea
- 3Institute of Health Science, Gyeongsang National University College of Medicine, Jinju, Korea
- 4Department of Neurology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
- 5Department of Neurology, Gyeongsang National University Changwon Hospital, Changwon, Korea
- KMID: 2529613
- DOI: http://doi.org/10.17340/jkna.2022.2.14
Abstract
- Monoclonal antibodies are pure antibodies that react to a specific epitope. Plasmapheresis is a treatment that separates and eliminates disease-causing substances before replacing the blood with plasma. Plasmapheresis has insufficient evidence for treating new-onset refractory status epilepticus (NORSE). Sequential plasmaphereses gradually improved a female cryptogenic NORSE patient who did not benefit from monoclonal antibody treatment.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Consciousness Recovery by Rituximab after Seizure Control in Cryptogenic New-Onset Refractory Status Epilepticus
- Sevoflurane for the Management of Refractory Status Epilepticus : A case report
- Status Epilepticus and Beyond: A Clinical Review of Status Epilepticus and an Update on Current Management Strategies in Super-refractory Status Epilepticus
- Anesthetic experience for performing a cesarean section for a woman with refractory status epilepticus: A case report
- Management strategies for refractory status epilepticus
